
In today’s briefing:
- BYD (1211 HK): Sales Volume Slowing Down in 2Q25, But Competitors Facing Cash Flow Stress
- Ascentage Pharma Top-Up Placement – Past Deals Didn’t Done Well, Stock up a Lot but Sector Is Strong
- Guangdong-Hong Kong Greater Bay Area (1396 HK): This Doesn’t Add Up
- Quiddity Leaderboard CSI 300/500 Dec25: Some Changes to Expectations; Large Index Flows
- Meituan (3690): Full Round-Trip, Surge in Call Volumes Provide Strong Trade Setup
- Hong Kong Financials in Focus: Sub-Sector Option Volumes Reveal Emerging Themes
- BYD (1211 HK) Outlook Under Pressure as Sales Momentum Fades
- CICC (3908 HK): It Is the Best of the Time
- Pre-IPO Busy Ming Group – Concerns Behind the High Growth
- MegaRobo Technologies IPO Preview: AI-Driven Robotics Unicorn With Strong IP Moat In Automation

BYD (1211 HK): Sales Volume Slowing Down in 2Q25, But Competitors Facing Cash Flow Stress
- The sales volume growth rate slowed down month by month in 2Q25.
- The domestic sales volume was stagnant in 2Q25 and decreased YoY from March to June.
- However, competitors expanded aggressively; therefore, we believe small ones may go bankrupt.
Ascentage Pharma Top-Up Placement – Past Deals Didn’t Done Well, Stock up a Lot but Sector Is Strong
- Ascentage Pharma Group Corp (6855 HK) (AP) aims to raise around US$196m via top-up placement.
- The company has undertaken a number of deals in the past, with none of the deals having done well. Although stock momentum has been strong this year.
- In this note, we will talk about the deal dynamics and run the deal through our ECM framework.
Guangdong-Hong Kong Greater Bay Area (1396 HK): This Doesn’t Add Up
- Property developer Guangdong – Hong Kong Greater Bay Area Holdings (1396 HK) (GHKGBA) is currently suspended pursuant to the Takeovers Code.
- GHKGBA, previously known as Hydoo, was subject to an unconditional MGO in 2019 after China Guangdong-Hong Kong Greater Bay Area (CGHKGBA) acquired a 51.56%. CGHKGBA currently holds a 50.94% stake
- At a guess, CGHKGBA will seek to take GHKGBA private by way of a Scheme. The rub/pushback? GHKGBA’s share price is up 2,383% YTD. And trailing P/B is ~7x.
Quiddity Leaderboard CSI 300/500 Dec25: Some Changes to Expectations; Large Index Flows
- CSI 300 represents the 300 largest stocks by market cap and liquidity from the Shanghai and Shenzhen Exchanges. CSI 500 is the next 500 names.
- In this insight, we take a look at the potential ADDs and DELs leading the race for the semiannual index rebal event in December 2025.
- Currently, we see 9 ADDs/DELs for the CSI 300 index and 45 ADDs/DELs for the CSI 500 index.
Meituan (3690): Full Round-Trip, Surge in Call Volumes Provide Strong Trade Setup
- Meituan has completed a full roundtrip from its 2024 rally and is now back near key support.
- Option traders have taken notice, with a notable pickup in activity—especially for Calls.
- We outline two trade structures depending on directional or vol views.
Hong Kong Financials in Focus: Sub-Sector Option Volumes Reveal Emerging Themes
- Volume trends and sub-sector splits highlight where interest is most concentrated.
- We revisit top names that appeared prominently in last week’s active lists
- Trading patterns suggest a mix of positioning motives across Financial names.
BYD (1211 HK) Outlook Under Pressure as Sales Momentum Fades
- BYD (1211 HK) fell for longer than expected since our last insight was published. We said that if BYD was going to fall below 120, the trend would become bearish.
- The stock did not fall a lot, it briefly reached below our 120 support level (75% probability of reversal), but has been down for 5 weeks. It is oversold.
- The big question now is: can BYD recover and start to trend up again? Or are we going to see a small bounce from oversold levels, followed by lower prices?
CICC (3908 HK): It Is the Best of the Time
- China International Capital Corporation (3908 HK)‘s 1H25 positive profit alert is encouraging, with 1H25 results growing by 55-78% YoY.
- YTD, CICC has a 59.5% share of the HK IPO market. The solid H-share IPO pipeline of A-share companies is beneficial, as this is its major area of strength.
- Market consensus has underestimated its FY25 earnings, inflating its PER multiples. The current 51% discount of its H-share to A-share is just too steep (average 37.7%).
Pre-IPO Busy Ming Group – Concerns Behind the High Growth
- BUSY MING operates under the franchise model, under which franchisees and BUSY MING form collaboration and a virtuous cycle, benefiting from the ecological logic of high turnover.
- However, the potential risk is increasing homogeneous competition. Price wars and competitors’ rapid expansion would further squeeze the profit margin of BUSY MING and lead to market oversaturation.
- The current high growth may not sustain.BUSY MING clearly hopes to successfully IPO during the current peak period of performance, but investors may face a decline in performance after IPO.
MegaRobo Technologies IPO Preview: AI-Driven Robotics Unicorn With Strong IP Moat In Automation
- MegaRobo Technologies, AI & robotics unicorn with focus on lab automation in life sciences and intelligent manufacturing, files to list IPO on Hong Kong Stock Exchange.
- Founder led, AI native company was backed by Sinovation Ventures, Goldman Sachs, Asia Investment Capital, Robert Bosch Venture Capital, GGV Capital, and Joy Capital, among others.
- The business is growing fast and increases the number of use cases across new verticals. However, negative free cash flows and operating losses are a headwind.